{"page":{"totalFilteredElements":46},"studies":[{"active":true,"description":"NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","eudractNumber":"2024-516734-35-00","id":12038,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07178730","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-11-05T10:31:49+01:00","shortTitle":"ADAPT-TN-IV","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Adjuvant Dynamic marker - Adjusted Personalized Therapy \ncomparing adjuvant Elacestrant with standard endocrine \ntreatment in genomically and/or clinically high-risk ER+/HER2- \nearly breast cancer","eudractNumber":"2025-522484-15-00","id":12036,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT07242352","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-06-23T09:18:11+02:00","shortTitle":"ADAPTela","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Prospektive, multizentrische Registerstudie zur Bewertung verschiedener leitlinienkonformer Operationsverfahren in der Axilla (Sentinel-Node Biopsie, Targeted Axillary Dissection, Axilladissektion) nach neoadjuvanter Chemotherapie","eudractNumber":null,"id":7644,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04373655","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2020-06-04T13:27:58+02:00","shortTitle":"AXSANA / EUBREAST 3 – Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<p class=\"MsoNormal\">A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants with Advanced Solid Tumors<br /></p><p class=\"MsoNormal\">EUDRA-CT Nummer ge&#228;ndert 18.12.2023<br /></p><p class=\"MsoNormal\">von 2021-001188-26 auf&#160; 2023-503651-10-00<br /></p>","eudractNumber":"2023-503651-10","id":7045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04895709 ","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-07-14T13:04:26+02:00","shortTitle":"BMS CA052-002","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"RNA Disruption Assay (RDA) <b>Br</b>east cancer <b>R</b>esponse <b>EV</b>aluation for<b> I</b>ndividualized <b>T</b>herap<b>Y</b>-02 (BREVITY-02)","eudractNumber":null,"id":7611,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03524430","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-03-26T10:16:13+01:00","shortTitle":"BREVITY-02","therapeutical":false,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"A Phase 2\nOpen-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination\nwith Other Agents in Participants with Advanced and/or Metastatic Solid Tumors\nwith Homozygous MTAP Deletion","eudractNumber":"2025-524285-18","id":11869,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"MTAP (methylthioadenosine phosphorylase)","id":"mt_260"}],"nctNumber":"NCT07492680","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2026-10-14T13:30:01+02:00","shortTitle":"BZKF BMS CA240-005","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Machbarkeit einer Lebensstilintervention zur Umstellung auf ballaststoffreiche und darmgesunde Kost bei Frauen mit Triple-Negativem Mammakarzinom unter Immuntherapie in der Neoadjuvanz&#160;","eudractNumber":null,"id":11704,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07311083","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-09-28T10:49:59+02:00","shortTitle":"BallastImmun","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Hirnmetastasen im Brustkrebs-Netzwerk Deutschland<div>DRKS00011830</div>","eudractNumber":null,"id":7905,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-01-01T08:34:03+01:00","shortTitle":"Brain Metastases in Breast Cancer Network - BMBC (GBG 79)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive und Retrospektive Registerstudie der German Breast Group (GBG) Zur Diagnostik und Therapie des Mammakarzinoms in der Schwangerschaft mit jungen, nicht schwangeren Patientinnen (&lt;40Jahre) als Vergleichskohorte","eudractNumber":null,"id":6193,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT00196833","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2013-01-01T10:24:09+01:00","shortTitle":"Breast Cancer in Pregnancy (BCP)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular patterns of Ribociclib efficacy and resistance in advanced breast cancer patients","eudractNumber":"2022-000637-16","id":8438,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"PgR-","id":"mt_50"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT05452213","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2022-11-23T12:26:12+01:00","shortTitle":"CAPTOR-BC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]}]}